Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma Interventions:   Drug: Lenvatinib;   Drug: Placebo;   Drug: Immunosuppressive regimen Sponsor:   RenJi Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: Available online 5 December 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Waseem Amjad, Sandy Kotiah, Ankur Gupta, Michael Morris, Li Liu, Paul J. ThuluvathAbstractThe use of immunotherapy in transplant recipients is considered a contraindication because of very high risks for graft loss. The graft loss is to be expected since cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and PD-1 pathways are implicated in graft tolerance. In this case report, we describe a woman with recurrent, disseminated hepatocellular carcinoma who was successfully treated with nivolumab, an immune checkpoint inhibitor.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Publication date: Available online 4 December 2019Source: Hepatobiliary &Pancreatic Diseases InternationalAuthor(s): Yasuhiko Sugawara
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
AbstractObjectiveTo investigate the performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 treatment response algorithm for predicting hepatocellular carcinoma (HCC) viability after locoregional therapy (LRT) using the liver explant as reference.MethodsOne hundred fourteen patients with 206 HCCs who underwent liver transplantation (LT) after LRT for HCCs were included in this retrospective study. Two radiologists independently evaluated tumor viability using the LI-RADS and modified RECIST (mRECIST) with CT and MRI, respectively. The sensitivity and specificity of arterial phase hyperenhancement (APHE) and ...
Source: European Radiology - Category: Radiology Source Type: research
AbstractLiver transplantation has become a definitive treatment for patients with end-stage liver disease and those meeting Milan criteria for hepatocellular carcinoma. The morbidity and mortality associated with liver transplantation continues to decrease thanks to refinements in surgical technique, immunosuppression, and imaging. In particular, imaging plays a vital role by facilitating early detection of post-operative complications and enabling prompt treatment. Post-operative complications that lead to graft failure and patient morbidity/mortality can be generally categorized as vascular, biliary, parenchymal, and mal...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Conclusions: Patients with HCC and HH can achieve comparable survival rates following curative or LRT modalities to other liver diseases. The BCLC staging system accurately stratifies survival and excellent 5-year survival is possible following LT in selected patients.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
Conclusions. Hispanic patients with cirrhosis experience a survival advantage over many other racial groups despite adjustment for multiple covariates.
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—Liver Source Type: research
This article revises the characteristics of portal vein thrombosis on contrast-enhanced ultrasonography in order to determine its accuracy in the diagnosis of malignant portal vein thrombosis.
Source: Ultrasound Quarterly - Category: Radiology Tags: Pictorial Essay Source Type: research
Hepatitis C (HCV) is the most common chronic blood-borne illness in the United States, estimated to affect 2.7 to 3.9 million persons [1,2]. A leading cause of end stage liver disease, hepatocellular carcinoma, and liver transplantation [2 –4], HCV is now responsible for more deaths annually in the U.S. than HIV, tuberculosis, and 58 other nationally reportable infectious diseases combined [5]. As an estimated three quarters of HCV-infected individuals in the U.S. were born between 1945 and 1965, the Centers for Disease Control and Prevention (CDC) and United States Preventive Services Task Force (USPSTF) issued reco...
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research
This article reviews the mechanisms of carcinogenic HBV by conducting a review of the literature on the efficacy of therapy for reducing the risk of HCC. A few recent articles have suggested that tenofovir offers advantages over entecavir in terms of HCC prevention, but these articles have the inherent limitations of observational data. No other head-to-head randomized trials exist. Further randomized studies would help provide stronger evidence of the association between the type of antiviral agent and the HCC outcomes. Only achieving complete viral eradication from the liver will truly decrease the mortality and incidenc...
Source: Korean J Gastroenter... - Category: Gastroenterology Authors: Tags: Korean J Gastroenterol Source Type: research
Publication date: Available online 22 November 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Sirina Ekpanyapong, Neil Philips., Bao-Li Loza, Peter Abt, Emma E. Furth, Rashmi Tondon, Vandana Khungar, Kim Olthoff, Abraham Shaked, Maarouf A. Hoteit, K. Rajender ReddyAbstractBackgroundLiver transplantation (LT) is an accepted therapeutic option for hepatocellular carcinoma (HCC) in patients with cirrhosis. Despite careful candidate selection, HCC recurrence occurs. We aimed to describe the predictors of recurrence, clinical presentation, and predictors of survival after HCC recurrence post-LT.MethodsPat...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver | Liver Cancer | Liver Transplant | Research | Transplants | Urology & Nephrology